Month: January 2021
Excerpt from the Article: How well a patient’s lungs recover post-COVID-19 infection is not necessarily linked with the severity of his or her disease course, but imaging shows that most patients do not experience long-term fibrosis. To date, little research has focused on lung health post-recovery, and not much is known about whether the lingering…
Read More
Excerpt from the Press Release: Phase 2 clinical trial of Brilacidin for COVID-19 anticipated to commence this month Email Print Friendly ShareJanuary 14, 2021 07:30 ET | Source: Innovation Pharmaceuticals Inc. WAKEFIELD, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) — Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to announce that the…
Read More
Excerpt from the Article: Chest CT scans can provide a volumetric analysis of lung consolidation in COVID-19-positive patients, helping providers with care management and better enabling them to pinpoint which patients could die in the hospital from the virus. In a study published Jan. 6 in the European Journal of Radiology Open, investigators from Michigan…
Read More
Excerpt from the Article: Donor plasma from patients who have recovered from COVID-19 can reduce deaths in others if given early and at high enough doses, Mayo Clinic researchers found. The discovery validates one of COVID-19’s only known treatments, which will be relied on until an increase in vaccinations snuffs out the global pandemic, said…
Read More
Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)– Illumina, Inc. (Nasdaq: ILMN) and Helix today announced a collaboration to augment national surveillance infrastructure in the US to track the emergence and prevalence of novel strains of SARS-CoV-2 with support from the CDC. The combination of Illumina’s sequencing technology and expertise and Helix’s national COVID-19 testing…
Read More
WARRINGTON, Pa., Jan. 6, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced that it has dosed the first patient in its Phase 2 clinical trial studying lucinactant in acute lung injury in adults with COVID-19 associated…
Read More
Excerpt from the Press Release: PHILADELPHIA—Medications to treat high blood pressure did not affect outcomes among patients hospitalized with COVID-19, found an international team led by researchers in the Perelman School of Medicine at the University of Pennsylvania. The study, published today in The Lancet Respiratory Medicine, is the first randomized controlled trial to show…
Read More
Excerpt from the Press Release: Burlingame, CA, and Chicago, IL – January 10, 2021 – Humanigen, Inc. (HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab™, and EVERSANA, a pioneer of next-generation services to the global life sciences industry, today announced…
Read More
Excerpt from the Article: eRegulatory binders help clinical sites organize and digitize the regulatory process. In this post, we take a brief look at what every FDA-regulated binder needs to have. As a research coordinator or administrator, you’re responsible for managing forms, signatures, monitor visits, regulatory documentation and more. Not to mention squeezing in patient-related…
Read More
Excerpt from the Press Release: SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) — AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and COVID-19 research, announced today that it has released a preprint of its manuscript describing the development of ImmunoPass, the Company’s rapid point-of-care test that semi-quantitatively…
Read More